Quality of life issues in relation to the aromatase inhibitor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 168-172

  Fallowfield, Lesley ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Aromatase; Quality of life

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOTOXIC AGENT; EXEMESTANE; FULVESTRANT; GONADORELIN DERIVATIVE; LETROZOLE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADVANCED CANCER; ALOPECIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COGNITION; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSPAREUNIA; FOLLOW UP; HOT FLUSH; HUMAN; LIBIDO DISORDER; LONG TERM CARE; MOOD CHANGE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER; VAGINA DISCHARGE; VAGINAL DRYNESS; VOMITING;

AROMATASE INHIBITORS; COGNITION; HUMANS; QUALITY OF LIFE; SOCIETIES, MEDICAL;

EID: 34548400314     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.003     Document Type: Article

References (33)

1. Buzdar A., Howell A., Cuzick J., Wale C., Distler W., Hoctin-Boes G., Houghton J., Locker G.Y., and Nabholtz J.M. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7 (2006) 633-643
2. Whelan T.J., and Pritchard K.I. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin. Cancer Res. 12 (2006) 1056s-1060s
3. Fellowes D., Fallowfield L.J., Saunders C.M., and Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?. Breast Cancer Res. Tr. 66 (2001) 73-81
4. Duric V.M., Fallowfield L.J., Saunders C., Houghton J., Coates A.S., and Stockler M.R. Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?. Brit. J. Cancer 93 (2005) 1319-1323
5. Fromme E.K., Eilers K.M., Mori M., Hsieh Y.C., and Beer T.M. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 22 (2004) 3485-3490
6. Coombes R.C., Bliss J.M., Hall E., Gibson L., and Fallowfield L. Under-reporting of symptoms in patients with early breast cancer who have received tamoxifen for 2-3 years. Proceedings of the American Society for Clinical Oncology (2003)
7. Savage C., Pater J.L., Tu D., and Norris B. He said/she said: how much agreement is there on symptoms between common toxicity criteria and quality of life/. Proceedings of the American Society for Clinical Oncology (2002)
8. Atkins L., and Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur. J. Cancer 42 (2006) 2271-2276
9. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., and Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
10. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., and Tobias J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
11. Fallowfield L., Fleissig A., Edwards R., West A., Powles T.J., Howell A., and Cuzick J. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J. Clin. Oncol. 19 (2001) 1885-1892
12. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L., and Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol. 17 (1999) 2659-2669
13. Ganz P.A. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J. Natl. Cancer Inst. Monogr. (2001) 130-134
14. Fallowfield L.J., Leaity S.K., Howell A., Benson S., and Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res. Tr. 55 (1999) 189-199
15. Brady M.J., Cella D.F., Mo F., Bonomi A.E., Tulsky D.S., Lloyd S.R., Deasy S., Cobleigh M., and Shiomoto G. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J. Clin. Oncol. 15 (1997) 974-986
16. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J. Clin. Oncol. 22 (2004) 4261-4271
17. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., and Howell A. Quality of Life of Postmenopausal Women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res. Tr. 100 3 (2006) 273-284
18. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., and Bliss J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
19. Coombes R.C., Paridaens R., Jassem J., van de Velde C.J., Delozier T., Jones S.E., Hall E., Kilburn L.S., Snowdon C.F., and Bliss J.M. First mature analysis of the Intergroup Exemestane Study. Proceedings of the American Society for Clinical Oncology abstr. LBA527 (2006)
20. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., Coombes R.C., and Hall E. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J. Clin. Oncol. 24 (2006) 910-917
21. Asmar L., and Jones S.E. Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane or tamoxifen in a blinded adjuvant study. San Antonio Breast Cancer Symposium. Texas. Breast Cancer Res. Tr. (2005)
22. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., and Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97 (2005) 1262-1271
23. Hilditch J.R., Lewis J., Peter A., van Maris B., Ross A., Franssen E., Guyatt G.H., Norton P.G., and Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24 (1996) 161-175
24. Lash T.L., Fox M.P., Westrup J.L., Fink A.K., and Silliman R.A. Adherence to tamoxifen over the five-year course. Breast Cancer Res. Tr. 99 2 (2006) 215-220
25. Partridge A.H., Wang P.S., Winer E.P., and Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21 (2003) 602-606
26. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., Morris R., and Price M. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann. Oncol. 17 (2006) 205-210
27. Pandya K.J., Morrow G.R., Roscoe J.A., Zhao H., Hickok J.T., Pajon E., Sweeney T.J., Banerjee T.K., and Flynn P.J. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 366 (2005) 818-824
28. Loprinzi C.L., Levitt R., Barton D., Sloan J.A., Dakhil S.R., Nikcevich D.A., Bearden III J.D., Mailliard J.A., Tschetter L.K., Fitch T.R., and Kugler J.W. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J. Clin. Oncol. 24 (2006) 1409-1414
29. Hickey M., Saunders C.M., and Stuckey B.G. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol. 6 (2005) 687-695
30. Filshie J., Bolton T., Browne D., and Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients-audit and treatment algorithm. Acupunct. Med. 23 (2005) 171-180
31. Jenkins V., Shilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13 (2004) 61-66
32. Castellon S., Ganz P., Bower J., Petersen L., Abraham L., and Greendale G. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 26 (2004) 955-969
33. Shilling V., Jenkins V., and Trapala I.S. The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res. Tr. 95 (2006) 125-129